Literature DB >> 18279955

Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.

Min Huang1, Yanhong Wang, Jingjin Gu, Jing Yang, Karen Noel, Beverly S Mitchell, Vern L Schramm, Lee M Graves.   

Abstract

Immucillin-H (BCX-1777, forodesine) is a transition state analogue and potent inhibitor of PNP that shows promise as a specific agent against activated human T-cells and T-cell leukemias. The immunosuppressive or antileukemic effects of Immucillin-H (ImmH) in cultured cells require co-administration with deoxyguanosine (dGuo) to attain therapeutic levels of intracellular dGTP. In this study we investigated the requirements for sensitivity and resistance to ImmH and dGuo. (3)H-ImmH transport assays demonstrated that the equilibrative nucleoside transporters (ENT1 and ENT2) facilitated the uptake of ImmH in human leukemia CCRF-CEM cells whereas (3)H-dGuo uptake was primarily dependent upon concentrative nucleoside transporters (CNTs). Analysis of lysates from ImmH-resistant CCRF-CEM-AraC-8D cells demonstrated undetectable deoxycytidine kinase (dCK) activity, suggesting that dCK and not deoxyguanosine kinase (dGK) was the rate-limiting enzyme for phosphorylation of dGuo in these cells. Examination of ImmH cytotoxicity in a hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient cell line CCRF-CEM-AraC-8C, demonstrated enhanced sensitivity to low concentrations of ImmH and dGuo. RT-PCR and sequencing of HGPRT from the HGPRT-deficient CCRF-CEM-AraC-8C cells identified an Exon 8 deletion mutation in this enzyme. Thus these studies show that specific nucleoside transporters are required for ImmH cytotoxicity and predict that ImmH may be more cytotoxic to 6-thioguanine (6-TG) or 6-thiopurine-resistant leukemia cells caused by HGPRT deficiency.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279955      PMCID: PMC2494856          DOI: 10.1016/j.leukres.2007.12.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  32 in total

1.  Accumulation of somatic mutations in proliferating T cell clones from children treated for leukemia.

Authors:  B A Finette; A C Homans; J Rivers; T Messier; R J Albertini
Journal:  Leukemia       Date:  2001-12       Impact factor: 11.528

2.  Acquired DNA mutations associated with in vivo hydroxyurea exposure.

Authors:  V N Hanft; S R Fruchtman; C V Pickens; W F Rosse; T A Howard; R E Ware
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

3.  A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Authors:  Varsha Gandhi; John M Kilpatrick; William Plunkett; Mary Ayres; Leigh Harman; Min Du; Shanta Bantia; Jan Davisson; William G Wierda; Stefan Faderl; Hagop Kantarjian; Deborah Thomas
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

4.  Immucillin-H binding to purine nucleoside phosphorylase reduces dynamic solvent exchange.

Authors:  F Wang; R W Miles; G Kicska; E Nieves; V L Schramm; R H Angeletti
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

5.  Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine.

Authors:  J L Ward; A Sherali; Z P Mo; C M Tse
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 6.  Purine nucleoside phosphorylases: properties, functions, and clinical aspects.

Authors:  A Bzowska; E Kulikowska; D Shugar
Journal:  Pharmacol Ther       Date:  2000-12       Impact factor: 12.310

7.  Spontaneous frequency of exon skipping in the human HPRT gene.

Authors:  A Skandalis; P J Ninniss; D McCormac; L Newton
Journal:  Mutat Res       Date:  2002-04-25       Impact factor: 2.433

8.  Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.

Authors:  J R Hammond
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-04       Impact factor: 3.000

9.  Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.

Authors:  G A Kicska; L Long; H Hörig; C Fairchild; P C Tyler; R H Furneaux; V L Schramm; H L Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

Review 10.  Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.

Authors:  Vern L Schramm
Journal:  Biochim Biophys Acta       Date:  2002-07-18
View more
  9 in total

Review 1.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

2.  Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Dushyant Verma; Susan O'Brien; John Michael Kilpatrick; Yuling Chen; Brenita F Tyler; Susan Bickel; Shanta Bantia; Michael J Keating; Hagop Kantarjian; Varsha Gandhi; Farhad Ravandi
Journal:  Blood       Date:  2010-04-28       Impact factor: 22.113

3.  Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Gary B Evans; Keith Clinch; Douglas R Crump; Lawrence D Harris; Richard F G Fröhlich; Peter C Tyler; Keith Z Hazleton; María B Cassera; Vern L Schramm
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

4.  Intracellular rebinding of transition-state analogues provides extended in vivo inhibition lifetimes on human purine nucleoside phosphorylase.

Authors:  Sara T Gebre; Scott A Cameron; Lei Li; Y S Babu; Vern L Schramm
Journal:  J Biol Chem       Date:  2017-08-09       Impact factor: 5.157

5.  The effects of forodesine in murine and human multiple myeloma cells.

Authors:  Liesbeth Bieghs; Jo Caers; Elke De Bruyne; Els Van Valckenborgh; Fiona Higginbotham; Karin Vanderkerken; Eline Menu
Journal:  Adv Hematol       Date:  2010-10-19

Review 6.  Immucillins in Infectious Diseases.

Authors:  Gary B Evans; Peter C Tyler; Vern L Schramm
Journal:  ACS Infect Dis       Date:  2017-12-05       Impact factor: 5.084

Review 7.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

8.  Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Alice Bertaina; Franco Locatelli; Andrea Pession; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; Laura Zambonin; Luca Maria Neri; Alberto Maria Martelli; Francesca Chiarini
Journal:  J Hematol Oncol       Date:  2016-10-24       Impact factor: 17.388

Review 9.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.